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The discovery of the genetic basis of inherited arrhythmias has paved the way for an improved understanding of 
arrhythmogenesis in a wide spectrum of life-threatening conditions. In vitro expression of mutations and trans-
genic animal models have been instrumental in enhancing this understanding, but the applicability of results to the 
human heart remains unknown. The ability to differentiate induced pluripotent stem cells (iPSs) into cardiomyo-
cytes enables the potential to generate patient-specific myocytes, which could be used to recapitulate the features 
of inherited arrhythmias in the context of the patient’s genetic background. Few studies have been reported on 
iPS-derived myocytes obtained from patients with heritable arrhythmias, but they have demonstrated the applica-
bility of this innovative approach to the study of inherited arrhythmias. Here we review the results achieved by iPS 
investigations in arrhythmogenic syndromes and discuss the existing challenges to be addressed before the use of 
iPS-derived myocytes can become a part of personalized management of inherited arrhythmias.
Introduction
The discovery of genes responsible for inherited arrhythmogenic 
syndromes has provided major insights in the pathophysiology of 
cardiac arrhythmias (1). In the last 20 years, the electrophysiologi-
cal mechanisms leading to sudden cardiac death in diseases such as 
long QT syndrome (LQTS), Brugada syndrome, and catecholamin-
ergic polymorphic ventricular tachycardia (CPVT) have been dissect-
ed, thanks to the in vitro characterization of human mutations in 
heterologous systems and the development of animal models (2, 3). 
However, animal models of inherited arrhythmias only approximate 
human mutations because of species differences in the electrophysi-
ological properties of the heart, thus limiting our understanding of 
pathogenesis and the development of targeted therapies. The heart 
rate of a mouse is around 600 beats per minute, ten times faster than 
that of human beings; as a consequence, the duration of the action 
potential is much shorter and ion channels have different proper-
ties. Although mutations inserted into the genome of heart cells of 
animals recapitulate some of the properties seen in affected patients 
(4, 5), not all observations in these models are applicable to humans. 
Though access to affected human cardiac tissue or cells would be 
ideal, until recently, deriving human myocytes from heart biopsies 
has been a very complex exercise.
One challenging aspect in understanding inherited arrhythmias 
is the evidence that the same genetic mutations may give rise to 
remarkably different clinical phenotypes in different family mem-
bers. Usually referred to as “variable penetrance of the disease,” 
this observation has been attributed to largely undefined genetic 
modifiers (6, 7). Studies of induced pluripotent stem cell–derived 
(iPS-derived) cells might shed light on the elusive role of genetic 
modifiers in arrhythmias (discussed in detail below).
Studies of patient-derived cardiomyocytes from differenti-
ated pluripotent stem cells could potentially provide a fascinat-
ing opportunity to make a quantum leap in the field (8). In the 
near future, skin cells from an individual affected by an inherited 
arrhythmic disease might be differentiated into cardiac cells that 
carry the genetic defect of the patient. The disease model thus 
obtained may be used to gain insight into the pathophysiology 
of the disease and identify targeted therapies for the individual 
patient, which is the ideal goal of personalized medicine.
Despite the appeal and technical feasibility of this concept, ini-
tial data have shown that the unique complexity of cardiac excit-
ability provides several challenges, and technical advances are 
required before the methods can be applied to the clinical setting.
In this review, we present the state of the art in using iPSs for the 
study of cardiac electrophysiology, highlighting the results achieved 
thus far and envisioning the promises and challenges of the field.
iPSs
Pluripotent stem cells are characterized by self-renewal and the 
capacity for differentiation into all somatic cell lineages (9). ES 
cells (ESCs), obtained from the inner cell mass of mouse embryos, 
were the first pluripotent cells isolated (10). ESCs have also been 
obtained from human embryos (11).
In addition to embryonic cells, differentiated somatic cells can 
be pluripotent with adequate reprogramming. As early as 1962, 
Gurdon demonstrated that nuclear transplantation of somatic 
nuclei into eggs could generate animals (12). More recently, 
Takahashi and Yamanaka found that mouse somatic cells 
could be reprogrammed into a pluripotent state through the 
overexpression of four transcription factors, OCT4, SOX2, KLF4, 
and MYC; the cells obtained in this way were termed iPSs (ref. 
13 and Figure 1). The four pluripotency factors initiate poorly 
defined epigenetic events that reactivate the endogenous pluri-
potency genes Oct4, Nanog, and Sox2 and promote an autoregu-
latory loop that maintains the pluripotent state independent of 
the transgenes (13). iPSs were later generated from adult human 
fibroblasts by defined factors (14).
Differentiation of pluripotent cells toward cardiomyogenic 
lineages
The differentiation of cardiac cells from ESCs mimics embryon-
ic processes specifying the cardiovascular lineage and involves a 
transition through a sequence of increasingly restricted progenitor 
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cells. In vitro, differentiation can be induced by suspending ESCs 
in medium with high levels of fetal calf serum to obtain three-
dimensional aggregates known as embryoid bodies (EBs) (15). 
Differentiated cell types of all three germ layers can be obtained 
by allowing the EBs to adhere to the culture substrate. However, 
this method is complex, time consuming, and above all can be 
poorly cardiogenic, with rhythmically contracting outgrowths in 
the 5%–15% range (16).
One serum-free, EB-based suspension technique has proven par-
ticularly effective for analyzing growth factor variables and timing 
during cardiac differentiation. In this protocol, EBs are formed 
in the presence of a low level of bone morphogenetic protein 4 
(BMP4) and then exposed to optimized levels of BMP4, FGF2, and 
activin A between days 1 and 4; VEGFA and dickkopf 1 (DKK1) 
from days 4 to 8; and VEGF and FGF2 from day 8 onward (17)
A simpler, monolayer-based method has also been developed, in 
which human pluripotent stem cells are cultured to a high density 
and then treated with a high dose of activin A, followed by 4 days 
of exposure to BMP4 (18). Contracting cardiomyocytes can be seen 
at day 12, with a purity of approximately 30%.
These reports indicate that correct dosing and timing of the 
right combination of growth factors has the utmost importance in 
inducing an efficient differentiation process. Much work is there-
fore focused on transferring developmental biology knowledge to 
approaches to derive cardiomyocytes from pluripotent cells and to 
study the differentiated cells produced.
Interestingly, recent data show that it is possible to knock out 
pathogenic genes in patient-derived cells after genetic modifica-
tion. This application of gene editing allows for the development 
of “isogenic controls” that may be used to define the effect of a 
mutation in the specific genetic environment of a given patient. 
Pioneers of this field have been Soldner et al. (19) and Liu et al. 
(20), who successfully restored the wild-type coding sequence in 
mutant patient-derived cells to correct phenotypes of Parkinson’s 
disease and progeria, respectively. Applying this technology to 
inherited arrhythmias may be particularly promising, allowing 
for a comparison of the phenotype of disease-carrying iPS-derived 
myocytes and their isogenic control myocytes.
Do iPS-derived myocytes reliably model the complexity 
of the human heart?
The electrical impulse is generated and propagated through 
a heterogeneous pool of cells in the heart. Each cell type (e.g., 
pacemaker cell, atrioventricular nodal cell, Purkinje fiber, atrial 
myocyte, ventricular myocyte) is characterized by a distinctive 
expression pattern of genes encoding a variety of ion chan-
nels that determine their specific electrophysiological profile. 
These electrophysiological properties of the heart develop dur-
ing embryogenesis and further mature postnatally; according-
ly, embryonic and fetal cells do not exhibit the same electrical 
behavior seen in adult myocytes (21).
The architecture of the electrical structure of the heart is 
highly sophisticated; even within a specific cell type, such as the 
ventricular cells, regional differences exist in the cellular elec-
trophysiological profile. Transmural sections of the ventricular 
wall are composed of different types of cells, such as epicardial, 
mid-myocardial, and endocardial, that have well-documented 
differences in electrical properties, as seen by the variable shape 
and duration of their action potentials (22). Similar differ-
ences exist between cells in the apex and the base of the heart 
and in the right versus the left ventricles (23). Even within the 
right ventricle, distinct electrical properties are present. Com-
pared with other ventricular regions, the outflow tract presents 
a delayed expression of proteins during development that are 
responsible for rapid conduction of the cardiac impulse, such 
as connexin 43 (Cx43) and Cx40 (24). During postnatal matura-
tion, this region of the right heart retains some slow conduction 
properties that may facilitate arrhythmogenesis (21, 24). This 
observation suggests that mutations in inherited arrhythmias 
may differentially affect cellular electrophysiology in the various 
heart cell types. It also raises the question whether iPS-derived 
myocytes are appropriate to study region-specific genetic condi-
tions such as Brugada syndrome, in which the RV outflow tract 
is the preferred arrhythmogenic site. Consequently, for iPS-
derived myocytes to reliably model patient arrhythmogenesis, 
the differentiated cells must replicate the complexity of electri-
cal heterogeneity in the human heart.
Action potential morphologies in iPS-derived myocytes
Electrical characterization of iPS-derived myocytes showed that 
the differentiation process of cardiac cells reflects, at least to 
some extent, the heterogeneity seen in the heart. Zhang et al. (25) 
performed a systematic study of the electrical properties of iPS-
derived cardiomyocytes using microelectrode recordings from 
spontaneously beating cells at 56–70 days after the formation of 
the EBs. These experiments identified three types of cardiac cells 
resembling atrial, ventricular, and nodal cells (i.e., cells from the 
AV node). As expected, the distinguishing feature of atrial cells 
was the reduced duration of the action potential and the lack of 
a plateau phase, whereas nodal cells were recognized by their pro-
nounced phase 4 depolarization preceding the onset of the action 
potential; ventricular cells presented the typical plateau phase 
and, therefore, had the longest action potential duration (APD). 
A striking feature of the published electrophysiology data on iPS-
derived myocytes is the impressive heterogeneity in the electrical 
parameters, such as the duration and amplitude of the action 
potential and the resting membrane potential. This heterogeneity 
suggests that cells obtained by different laboratories may not be 
similar and raises the question whether results are reproducible 
across research groups. A comparison of the electrophysiological 
properties of iPS-derived cardiomyocytes from published articles 
is summarized in Table 1. In these published studies, APDs at 50% 
and 90% of the amplitude (APD50 and APD90, respectively), for 
example, are very different even when the pacing rate is identical. 
These inconsistencies may be related to the different times elapsed 
between EB formation and the electrophysiological evaluation 
(Table 1). Differentiation protocols may also account for the devel-
opment of cells at variable stage of maturation. Malan et al. cir-
cumvent the problem of APD variability by studying the effect of 
pacing or drugs within a single cell in iPS-derived myocytes from 
genetically modified mice (26); this longitudinal approach could 
also be tested in human studies.
The key question that emerges is whether differentiated myo-
cytes obtained with available protocols provide a reproducible 
model for the adult human heart and, therefore, whether this 
model is applicable to the clinical setting. Based on the published 
data, iPS-derived myocytes appear to lack the distinction between 
epicardial and endocardial cells that occurs in adult mammalian 
ventricular myocytes. According to some authors, even the distinc-
tion between atrial-like and ventricular-like myocytes is blurred by 
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the existence of cells with an intermediate phenotype (27). Thus, 
some authors prefer to use the phrase “working myocardial cells” 
to cluster atrial-like and ventricular-like cells (see Table 1) and dis-
tinguish them from nodal cells (i.e., cells from the AV node). These 
observations point to the evidence that iPS-derived myocytes are 
at an early stage of differentiation with a continuous spectrum 
of electrical properties, resulting in heterogeneity. As discussed 
below, this observation is further supported by morphological 
evaluation of iPS-derived cardiac cells.
Ultrastructural properties of iPS-derived myocytes
An interesting study by Gherghiceanu et al. (28) reports important 
information on the ultrastructural characteristics of iPS-derived 
myocytes and compares them to human ESC-derived cardiomyo-
cytes. Interestingly, both cell types presented features of immature 
cells: large glycogen deposits, lipid droplets, large endoplasmic 
reticulum, rough endoplasmic reticulum, and an immature sar-
coplasmic reticulum (SR). The latter feature is more accentuated 
in iPS-derived myocytes. Remarkably, iPS-derived myocytes lack 
gap junctions, intercalated disks, and T tubules (despite the pres-
ence of caveolae, considered precursors to T tubules) (28). How-
ever, studies in cardiomyocytes derived from human ESCs have 
demonstrated the presence of gap junctions (29). In examining the 
entire EB, a progression of cell maturation was found — embryonic 
myocytes were present in the center of the EB, whereas cells located 
at the periphery of the EB were similar to fetal myocytes (29).
Modeling LQTS with iPS-derived myocytes
Although we have highlighted that iPS-derived myocytes obtained 
with the currently available differentiation protocols do not 
resemble adult myocytes, several studies have already characterized 
iPS-derived myocytes from patients with inherited arrhythmias, 
providing intriguing results (Table 1).
Figure 1
iPS generation, characterization, and derivation of beating cardio-
myocytes. (A) iPS generation strategy. Skin fibroblasts obtained from 
patients are expanded and transduced with a combination of embry-
onic genes (Oct4, Sox2, Klf4, Nanog, Linn28, and Myc). Transduced 
fibroblasts are maintained in an embryonic-specific medium supple-
mented with bFGF until iPS colonies appear. Clones are isolated man-
ually based on their ESC-like morphology and expanded for further 
characterization. (B) iPS characterization. Pluripotency marker expres-
sion (left) and developmental competence (right) should be evaluated 
to prove pluripotency of derived iPS lines. Analysis of the expression of 
typical markers of pluripotency in iPS progenitors includes expression 
of the “stemness” markers alkaline phosphatase, SSEA4, TRA-1-80, 
and OCT4 using FACS and immunofluorescence. Developmental 
competence is assessed both in vivo and in vitro. For in vivo analysis, 
teratoma formation assay is used: bona fide iPSs, when injected sub-
cutaneously into immunodeficient mice, can give rise to a teratoma 
containing the three germ layers (ectoderm, mesoderm, and endo-
derm). In vitro, iPSs are induced to differentiate through EB aggrega-
tion and give rise to cells of all three germ layers. Neuronal (β3-tubulin 
positive) and intestinal (AFP positive) markers indicate differentiation to 
ectodermal and endodermal lineages, respectively. (C) Generation of 
iPS-derived beating cardiomyocytes. Cardiac differentiation is induced 
by aggregation of EBs. The inductive process is enhanced in the pres-
ence of specific medium and ascorbic acid. Appearance of beating 
areas within the EBs is indicative of cardiomyocyte differentiation; cells 
are dissociated into single cells, which are analyzed for cardiac mark-
ers and electrophysiology.
LQTS is an inherited disease characterized by genetically deter-
mined prolongation of cardiac repolarization that is quantified 
as the duration of the QT interval on the ECG (30). The disease 
predisposes the heart to malignant ventricular tachyarrhythmia 
that may lead to sudden death. Most of the arrhythmic events 
in patients are precipitated by stress, emotion, or physical activ-
ity. Patients are usually treated with antiadrenergic therapy 
(β-blockers). The genes that cause LQTS encode either for sub-
units that form cardiac ion channels or for proteins that regulate 
the assembly and the localization of ion channels. The common 
functional consequence of mutations found in LQTS-related 
genes is the prolongation of cardiac action potential and induc-
tion of early afterdepolarizations (EADs) that result in the devel-
opment of a specific type of ventricular tachycardia called Torsade 
des pointes (Figure 1).
Moretti and coworkers (31) characterized for the first time 
iPS-derived myocytes from an LQTS patient carrying the R190W 
mutation in KCNQ1, which encodes the potassium channel that 
conducts the slow component of the delayed rectifier current (IKs) 
(Figure 2). Electrophysiological recording in iPS-derived myocytes 
has shown that (a) the R190W mutation prolongs the APD, (b) 
the IKs current in R190W myocytes is dramatically reduced, pos-
sibly because of a trafficking defect, and (c) adrenergic stimula-
tion facilitates development of EADs in R190W myocytes, whereas 
β-blockers revert the arrhythmogenic effect of β-adrenergic stimu-
lation. These observations showed that iPS-derived cells replicate 
the clinical features of the disease (QTc prolongation, proar-
rhythmic effect of adrenergic activation, and protective action of 
β-blockers) and reproduce results of functional characterization 
of the R190W mutation in heterologous systems (reduction the 
IKs current and trafficking defect) (32).
Three additional reports investigated the properties of iPS-
derived myocytes of LQTS patients carrying a mutation in the 
KCNH2 gene, which encodes for the channel that conducts the 
rapid component of the delayed rectifier current (IKr) (33–35). 
Studies by Itzhaki et al. (33) and Matsa et al. (35) characterized 
cells derived from carriers of mutations localized in the pore 
region of the HERG channel (A561T and A614V), known to cause 
a severe form of LQTS. As expected, both studies showed that the 
iPS-derived myocytes from affected individuals have prolonged 
APD and a decreased IKr current. Moreover, pharmacological chal-
lenges showed that the IKr blocking compound E4031 further pro-
longed repolarization in iPSs from LQTS patients and induced 
or worsened the EADs. In a related study, Lahti et al. (34) char-
acterized iPS-derived myocytes from a carrier of a mild missense 
mutation in the KCNH2 gene. The mutation causes the replace-
ment of an arginine residue at position 176, corresponding to the 
cytoplasmic N terminus of the channel (R176W). The patient that 
donated a skin biopsy for the research protocol was asymptom-
atic and presented a normal QT interval (QTc = 437 ms). Surpris-
ingly, however, the myocytes derived from the patient fibroblasts 
presented a marked prolongation of the APD90 that was approxi-
mately 170% that of the APD of cells derived from a control indi-
vidual (Table 1; APD90 in the R176W carrier, 516 ± 26 ms; APD90 
in a control individual, 310.5 ± 19.6 ms; data at 1 Hz pacing; 
P < 0.01). The discrepancy between the normal QTc of the patient 
and the marked prolongation of APD in iPS-derived myocytes is 
hard to explain and questions the ability of iPS-derived myocytes 
to predict QT prolongation in patients. Even more intriguing 
(and unexplained) is that in cells from the carrier of the R176W 
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mutation, despite an APD90 prolongation (166% of control) com-
parable to that observed in myocytes from carriers of the A614V 
(200%) and the A561T (188%) mutations, the occurrence of EADs 
in R176W myocytes was much lower. Unfortunately, it is not pos-
sible to determine whether the iPS-derived myocytes were truly 
able to predict symptoms or simply were unable to develop EADs 
because of lack of proper regulation of intracellular Ca2+ (iCa2+), 
because the authors did not study myocytes from asymptomatic 
family members who carried the R176W mutation.
Matsa et al. (35) obtained iPS-derived myocytes from two family 
members carrying the A561T mutation. In this study, the authors 
compared the cells derived from an asymptomatic mother carrier of 
the A561T mutation to cells derived from her highly symptomatic 
daughter. Consistent with the more severe clinical manifestations, 
the QTc was longer in the daughter (571 ms) than in the mother 
(514 ms). Interestingly, the APD90 was longer in the cells obtained 
from the daughter (the APD90 recorded from iPS-derived myo-
cytes from the daughter was 188% of the APD90 of control cells; in 
myocytes derived from the mother, APD90 was 150% of the value 
measured in control myocytes). Even more intriguingly, myocytes 
derived from maternal tissue failed to develop EADs, whereas after-
potentials developed in the cells from the symptomatic daughter.
As speculated by the authors, the lack of EADs in the iPS-derived 
myocytes obtained from the asymptomatic mother may reflect the 
effect of unrecognized genetic modifiers that may protect her cells 
from development of arrhythmias. Unfortunately, since Matsa et 
al. (35) did not demonstrate the presence of genetic or epigenetic 
factors that silence the effects of the mutation in the mother, the 
finding remains without mechanistic explanation.
The last characterization of iPS-derived myocytes from LQTS 
patients was performed by Yazawa et al. in two individuals 
affected by Timothy syndrome (LQT8) (36). LQT8 is caused 
by mutations in the gene encoding the L-type calcium chan-
nel CaV1.2 (CACNA1C) (37). This form of LQTS is a malig-
nant multisystem disorder that, in addition to causing car-
diac electrical vulnerability, induces cardiac malformations, 
syndactyly of the hands and feet, delayed social development, 
and autism. The majority of LQT8 patients carry the G406R 
missense mutation, which increases the inward calcium cur-
rent by altering voltage-dependent inactivation of the chan-
nel, leading to QT interval prolongation. This comprehensive 
study reported the electrophysiological properties of LQT8 
iPS-derived myocytes, documenting marked prolongation of 
APD and development of EADs and triggered beats. In addi-
tion, in iPS-derived myocytes from LQT8 patients, calcium 
transients presented irregular timing and irregular amplitude 
as compared with transients recorded in control iPS-derived 
myocytes. Finally, the authors tested the hypothesis that rosco-
vitine, a compound that increases the voltage-dependent inac-
tivation of the cardiac L-type calcium channels, may restore the 
electrical properties and Ca2+ signaling in cardiomyocytes from 
LQT8 patients. Roscovitine successfully abbreviated the action 
potential and abolished arrhythmogenic activity in myocytes 
from LQT8 patients. Although intriguing, the observation is 
not sufficient to support the notion that iPS-derived myocytes 
may help identify novel therapies for arrhythmogenic diseases 
because the efficacy of this therapeutic approach in humans 
has not yet been confirmed.
Table 1
Summary of studies of iPS-derived cardiomyocytes from patients with inherited arrhythmias
Phenotype N AP frequency MDP APA Maximal upstroke APD50 APD90 Age Syndrome Reference
  (Hz) (mV) (mV)  velocity (dV/dt) (ms) (ms) (d)
Control cells
Working 31 1.43 ± 0.11 –58 ± 1.6 97 ± 2.7 44 ± 6.7 145 ± 16 211 ± 17 20–25  27
Ventricular 32 1.70 ± 0.10 –76 ± 1.2 104 ± 1.1 28 ± 4.8  414 ± 22 30–32  46
Ventricular 37 0.73 ± 0.04 –63 ± 1.7 88 ± 2.6  241 ± 15 320 ± 17 10/20/30  25
Ventricular 39 0.73 ± 0.05 –63 ± 1.5 88 ± 2.4  239 ± 10 312 ± 11.20 10/20/30  25
Ventricular 40 1.00A –66 ± 1.2 108 ± 1.2  318 ± 19 373 ± 22 30–90 LQT1 31
Ventricular NA     221 ± 85B 297 ± 118B 25–30 LQT2 35
Ventricular 60 0.46 ± 0.10 –57 ± 1.0 109 ± 3 9.5 ± 1.8 308 ± 24B 436 ± 23B  LQT2 33
Ventricular 13 1.2 ± 0.10 –63 ± 1.3 113 ± 2.4  265 ± 15 311 ± 20  LQT2 34
Ventricular 16      400 ± 45B 37 LQT8 36
Ventricular 15       25 AD-CPVT 40
Ventricular 9 1.00 –75 ± 3.0   252 ± 29B  30–120 AD-CPVT 41
Working 10 0.64 ± 0.06 –58 ± 3.0B 99 ± 3B 6.20 ± 0.1B 201B ± 27B  21 AR-CPVT 43
Patient-derived cells
Ventricular 36 1.00A –67 ± 1.20 110 ± 1.3  481 ± 33 554 ± 35 30–90 LQT1 31
Ventricular NA     454 ± 90B 635 ± 119B 25–30 LQT2 35
Ventricular 58 0.26 ± 0.30 –55 ± 2 116 ± 4 10 ± 1.3 440 ± 9B 864 ± 8B  LQT2 33
Ventricular 13 0.90 ± 0.10 –62 ± 0.90 117 ± 1.4  455 ± 26 516 ± 26 180 LQT2 34
Working 16      1,130 ± 150B 37 LQT8 36
Ventricular 16 1.00A 79 ± 2.70B   234 ± 21B 293 ± 23B 60–120 AD-CPVT 41
Working 20  –56 ± 1B 98 ± 1.0B 7.60 ± 1.2B 368 ± 41B  21 AD-CPVT 43
Ventricular 24       25 AR-CPVT 40
AExperiments with electrically stimulated cells (nonspontaneous beating). BData derived from graphs. AD, autosomal dominant; AR, autosomal recessive; 
AP, action potential; MDP, maximum diastolic potential; APA, action potential amplitude.
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Modeling CPVT in iPS-derived myocytes
CPVT is an inherited arrhythmogenic disease (38) that occurs in 
patients with an unremarkable resting ECG and structurally intact 
heart. Adrenergic stimulation related to stress, emotion, or physi-
cal activity induces a peculiar form of life-threatening ventricular 
tachycardia called “bidirectional tachycardia.” Similar to LQTS 
patients, individuals with CPVT are treated with β-blockers to 
prevent arrhythmias. An autosomal dominant form of CPVT has 
been associated with mutations on RYR2, which encodes the car-
diac ryanodine receptor located in the SR of cardiomyocytes. The 
ryanodine receptor regulates calcium release from the SR to the 
cytosol to initiate cardiac contraction.
An autosomal recessive form of CPVT has been linked to muta-
tions in CASQ2, which encodes cardiac calsequestrin, a high-capac-
ity, low-affinity Ca2+-binding glycoprotein located inside the SR. 
Mutations in RYR2 and in CASQ2 lead to spontaneous diastolic 
calcium release, inducing delayed afterdepolarizations (DADs) and 
initiating arrhythmias (refs. 5, 39, and Figure 3).
Two studies characterized cardiomyocytes from iPSs obtained 
from patients with the dominant form of CPVT (40, 41). Fatima et 
al. (40) studied iPS-derived myocytes from a carrier of the F2483I 
mutation, located in the FKBP12.6 domain of RyR2. The muta-
tion was identified in an adult female patient that presented typi-
cal bidirectional ventricular tachycardia during an exercise stress 
Figure 2
Common mutations in LQTS. (A and B) Predicted transmembrane topology of KCNH2 and KCNQ1 proteins and the three LQT2 mutations (A) 
and one LQT1 mutation (B) studied in cardiomyocytes differentiated from iPSs obtained from tissues of affected patients. (C–E) Example of 
EADs and prolonged action potential (C), underlying QT prolongation with T wave morphological abnormalities (D), and polymorphic ventricular 
tachycardia (Torsade de Pointes) (E) observed in patients with LQTS.
Figure 3
CPVT. (A) Subcellular localization of the calcium-handling proteins involved in the pathogenesis of CPVT. The pathophysiology of both ryanodine 
receptor (RyR2) and calsequestrin (CASQ2) has been studied in cardiomyocytes differentiated from patient-derived iPSs. (B–D) The cellular and 
clinical phenotype of CPVT is shown, with an example of DADs and triggered activity recorded in cardiomyocytes isolated from the heart of a 
RyR2-R4496C knockin mouse (B), a resting electrocardiogram (C), and bidirectional ventricular tachycardia in a patient with CPVT (D).
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test. The authors differentiated iPS-derived myocytes from fibro-
blasts of the CPVT patient and demonstrated that cells presented 
the typical morphologies of atrial, ventricular, and nodal cells. 
Unfortunately, no data for APD were reported in the study, and 
the ventricular cells presented some features that are atypical of 
CPVT: upon administration of isoproterenol, control cells showed 
a physiological increase in the spontaneous beating rate, but 
myocytes derived from the CPVT patient had a negative chrono-
tropic response. This observation is inconsistent with the clinical 
response of CPVT patients to β-adrenergic stimulation. Patients 
usually show an acceleration of sinus rhythm and development 
of arrhythmias. Myocytes isolated from the heart of knockin mice 
for CPVT mutations also present acceleration of triggered rhythm 
during adrenergic stimulation (39). Another puzzling aspect of the 
study is the unusual morphology of the humps that were classified 
as DADs. These irregularly irregular wavelets did not present the 
typical morphology of DADs. Calcium imaging studies showed 
that, in agreement with a CPVT phenotype, iPS-derived myocytes 
from the CPVT patient presented abnormal spontaneous calcium 
transients characterized by higher amplitude and longer duration 
compared with healthy cardiomyocytes.
Jung et al. (41) reported data from iPS-derived CPVT myocytes 
carrying the S406L RyR2 mutation. Action potential recording 
experiments were performed, and it is not clear why the APD90 of 
iPS-derived ventricular myocytes from control patients was longer 
than APD90 recorded in myocytes from the CPVT patients (Table 1). 
This finding differs from clinical evidence that patients with CPVT 
have a slightly prolonged QT interval. This study clearly showed the 
presence of the frequency-dependent development of DADs (41). 
The authors also characterized calcium sparks in iPS -derived myo-
cytes from control and CPVT patients. Under basal conditions, Ca2+ 
spark frequency did not differ between control and CPVT myocytes, 
but Ca2+ spark amplitude was higher in diseased cells. During expo-
sure of cells to catecholamines, Ca2+ spark frequency considerably 
increased in CPVT cells compared with control cells.
Interestingly, Jung et al. (41) tested the ability of dantrolene to 
abolish triggered activity in iPS-derived myocytes. The demonstra-
tion that dantrolene is able to prevent arrhythmias in an knock-in 
mouse model of CPVT was previously reported (42), therefore Jung 
et al. tested whether the drug would be effective also in iPS-derived 
myocytes obtained from a CPVT patient carrier of the S406L muta-
tion. Dantrolene was indeed able to abolish DADs and suggesting 
that the drug may be effective also to treat CPVT in humans.
Novak et al. (43) studied iPS-derived myocytes obtained from 
patients with the D307H mutation in the gene encoding for car-
diac calsequestrin. This mutation has been extensively character-
ized, and it is associated with a very severe form of CPVT (44). The 
study adds to data from Jung et al. (41) and Fatima et al. (40), high-
lighting once more the susceptibility of iPS-derived CPVT myo-
cytes to the development of DADs and triggered activity. Perhaps 
most importantly, data obtained with electron microscopy showed 
that cells derived from CPVT patients present an immature mor-
phology with less-organized myofibrils, enlarged SR cisternae, 
and reduced number of caveolae. These data confirm data derived 
from knockout and knockin Casq2 mice showing that defective 
calsequestrin leads to ultrastructural abnormalities in the SR (5, 
45). Unfortunately, the level of CASQ2 in iPS-derived myocytes 
was not quantified to determine whether the protein is marked-
ly decreased, as observed in the studies performed in the trans-
genic mouse model carrier of the same mutation. In addition, the 
authors did not discuss how the absence of T tubules affected cal-
cium handling physiology. Considering that iPS-derived cells have 
an immature calcium-handling apparatus, the model may not be 
suitable to confirm observations made in animal models of CPVT.
Concluding remarks
A substantial amount of knowledge on the electrophysiological 
properties of iPS-derived myocytes has been collected. Data show 
that differentiation of stem cells into cardiomyocytes leads to the 
generation of immature cardiac cells that resemble fetal myocytes. 
According to most studies, iPS-derived myocytes have a depolarized 
resting membrane potential and a decreased Vmax (Table 1). Inter-
estingly, these myocytes lack gap junctions, intercalated disks, and 
T tubules. In order for the field to progress toward the clinical use 
of iPS-derived myocytes in predicting susceptibility to arrhythmias 
and response to therapy, the development of new differentiation 
protocols to produce iPS-derived myocytes with the electrophysi-
ological properties of adult cardiomyocytes and with a fully func-
tional calcium-handling apparatus will clearly be of paramount 
importance. Patch clamp studies and microelectrode recordings 
are technically challenging in iPS-derived myocytes and, therefore, 
a thorough characterization of the major ionic currents is still lack-
ing. Potentially, the introduction of automatic high-throughput 
electrophysiological analysis may overcome these limitations.
Studies published until now have successfully demonstrated 
that iPS-derived myocytes obtained from skin biopsies of affected 
individuals can recapitulate the key features of the disease. These 
results are important but do not support the claim that this tech-
nology is ready to enter the clinic. While it is clear that the predic-
tive value of the study of iPS-derived myocytes for individualized 
management of patients is still far from proven, it is reasonable to 
expect that this new model will provide additional insight in the 
biology of inherited arrhythmias in the short term, now that the 
critical proof-of-principle studies have been done.
These comments are not intended to shed a pessimistic view on 
the value of iPS-derived myocytes for the understanding of inher-
ited arrhythmias, but rather reflect a realistic assessment about 
where we stand and what needs to be improved, so that the field 
may mature toward its clinical potential.
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